[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arginine-vasopressin-deficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arginine-vasopressin-deficiency":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,74,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100636759","copeptin-measurement-after-mannitol-and-hypertonic-saline-for-the-diagnosis-of-polyuria-polydipsia-syndrome-100636759",false,"NCT07569861","Copeptin Measurement After Mannitol and Hypertonic Saline for the Diagnosis of Polyuria-polydipsia Syndrome","COMPASS","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Hypotonic polyuria\u002Fpolydipsia syndrome defined as polyuria \\>40ml\u002Fkg body weight\u002F24h and polydipsia \\>3l\u002F24h; and urine osmolality \\\u003C800mOsm\u002FL or known AVP-D based on accepted criteria\n\nExclusion Criteria:\n\n1. Polyuria\u002Fpolydipsia secondary to diabetes mellitus, hypercalcemia, or hypokalemia\n2. Diagnosis of AVP-R (Copeptin \\> 21.4 pmol\u002FL)\n3. Evidence of acute illness\n4. Epilepsy requiring treatment\n5. Uncontrolled arterial hypertension (blood pressure \\>160\u002F100mmHg at baseline\n6. eGFR \\\u003C 60 ml\u002Fmin\u002F1,73 m2\n7. Cardiac failure (NYHA III-IV)\n8. Diagnosis of liver cirrhosis, Child-Pugh Class C\n9. Uncorrected adrenal or thyroidal deficiency\n10. Pregnancy or breastfeeding\n11. Current or unresolved urinary obstruction\n12. Enrollment in a clinical trial within the last 30 days\n13. Patients refusing or unable to give written informed consent\n14. Inability to follow study procedures","ALL","18 Years",{"count":19,"type":20},144,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this study is to evaluate whether a new test using mannitol infusion can diagnose the cause of polyuria-polydipsia syndrome as accurately as the current standard test (hypertonic saline infusion) and to compare which test patients prefer. The goal is to identify a simpler and more patient-friendly diagnostic approach.",[26,27],"Arginine Vasopressin Deficiency","Primary Polydipsia",[29,30,31,32],"Copeptin Measurement","Diagnosis of Polyuria-polydipsia syndrome","Mannitol","Hypertonic Saline Infusion","RECRUITING","2026-06-17",{"date":36,"type":37},"2026-06-18","ACTUAL",{"date":39,"type":37},"2026-06-16",{"date":41,"type":20},"2030-06",{"name":43,"class":44},"University Hospital, Basel, Switzerland","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100636655","early-phase-1-identifying-oxytocin-deficiency-in-pediatric-patients-with-pituitary-disease-100636655","NCT07568509","Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease","Identifying a Provocation Test for Diagnosis of Oxytocin Deficiency in Youth With Hypopituitarism","Pedi-EVOLVE","Inclusion criteria (participants with AVP-D):\n\n* AVP-D diagnosed in clinic using standard of care diagnostic tools;\n* Stable pituitary hormone replacement (no change in dose of hormone replacement in six weeks prior to baseline);\n* If on estrogen\u002Fprogestin, female participants agree to stop for at least 6 weeks prior to Main study visits;\n* English language proficiency.\n\nInclusion criteria (participants with hypopituitary disease):\n\n* Hypopituitary disease diagnosis;\n* If receiving pituitary hormone replacement, no change in dose in six weeks prior to baseline);\n* If on estrogen\u002Fprogestin, participants agree to stop for at least 6 weeks prior to Main study visits;\n* English language proficiency.\n\nExclusion criteria (all participants):\n\n* History of pulmonary embolism or unprovoked deep venous thrombosis;\n* History of breast\u002Fendometrial cancer as well as current therapies on estrogen modulators\u002Fblockers (i.e., tamoxifen, raloxifene, aromatase inhibitors);\n* History of stroke, transient ischemic attack, myocardial infarction, angina pectoris, or peripheral arterial disease;\n* Pregnancy or breastfeeding within the last 8 weeks;\n* Medication changes within 2 weeks of enrollment or within 5 half-lives of the respective medication;\n* History of stage 3 chronic kidney disease or cirrhosis;\n* Any significant illness or condition that the investigator determines could interfere with study participation, data collection or safety;\n* Active tobacco smoking or nicotine patch use;\n* Psychosis or active suicidality.","7 Years","21 Years",{"count":57,"type":20},20,[59],"EARLY_PHASE1","An open-labeled, interventional pilot trial, 10 youth with AVP-D and 10 PD matched for age, sex, and BMI will be recruited from Pediatric Endocrinology and Neuroendocrinology at Massachusetts General Hospital and in the community. This study tests the hypothesis that oral estrogen\u002Fprogestin will stimulate endogenous oxytocin release in control subjects. Eligible participants will receive two tablets in a single administration containing a total of 1 mg of norethindrone acetate 70 mcg of ethinyl estradiol. Sampling for blood and saliva will take place at baseline and approximately 24 hours following study drug administration. Neuropsychological assessment (anxiety, mood and emotion regulation; impulse control; aberrant eating behaviors; social cognition and functioning; quality of life) will be assessed at baseline to characterize the study population.",[26,62,63,64],"Oxytocin Deficiency","Pediatric Disease","Hypopituitarism","2026-05-12",{"date":67,"type":37},"2026-05-15",{"date":69,"type":20},"2026-05",{"date":71,"type":20},"2027-04",{"name":73,"class":44},"Massachusetts General Hospital",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":45},"100578224","phase-2-effects-of-intranasal-oxytocin-on-sexual-well-being-in-patients-with-arginine-vasopressin-deficiency-and-healthy-controls-100578224","NCT06808516","Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls","The OxyPLEASURE Study - Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency (Central Diabetes Insipidus) and Healthy Controls - a Double-blind Randomized Placebo-controlled Crossover Trial","OxyPLEASURE","Inclusion Criteria for healthy controls:\n\n* Adult healthy volunteers aged 18 years and above\n* Matched for age, sex, BMI, and menopause\u002Fhormonal contraceptives to patients\n* No medication, except hormonal contraception\n* At least mild impairment in sexual function and satisfaction, defined as an ASEX-score ≥10 points and an NSSS-S score ≤ 48 points\n* Only Part A: Participants must be sexually active (at least once a week sexual intercourse) and in a current partnership for at least 6 months\n\nInclusion criteria for patients:\n\n* Adult patients aged 18 years and above, with a confirmed diagnosis of AVP deficiency based on established criteria\n* Stable hormone replacement therapy for at least three months with desmopressin and, in case of additional anterior pituitary deficiencies, with the respective substitution therapies\n* At least mild impairment in sexual function and satisfaction, defined as an ASEX-score ≥10 points and an NSSS-S score ≤ 48 points\n* Only Part A: Participants must be sexually active (at least once a week sexual intercourse) and in a current partnership for at least 6 months\n\nExclusion Criteria:\n\n* Pregnancy and breastfeeding within the last eight weeks\n* Participation in a trial with investigational drugs within 30 days\n* Active substance use disorder within the last six months\n* Consumption of alcoholic beverages \\>15 drinks\u002Fweek\n* Current or previous psychotic disorder (e.g., schizophrenia)",true,{"count":84,"type":20},42,[86],"PHASE2","The study aims to investigate whether intranasal oxytocin (OXT) improves sexual well-being in patients with Arginine Vasopressin Deficiency (AVP-D). The trial consists of two parts: Part A assesses the effect of OXT on sexual well-being and intimacy over a 7-day treatment period in participants in a stable partnership. Part B assesses the effect of a single dose OXT on sexual arousal, fear and empathy in a clinical setting and is designed for single participants and those in partnerships.",[26,89,62],"Central Diabetes Insipidus",[91,92],"Nasal oxytocin","Sexual Well-Being","2025-09-29",{"date":95,"type":37},"2025-10-03",{"date":97,"type":37},"2025-07-01",{"date":99,"type":20},"2026-12",{"name":43,"class":44},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":82,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":45},"100568096","phase-2-effect-of-intranasal-oxytocin-on-emotion-recognition-and-acute-psycho-social-stress-induced-cortisol-increase-in-patients-with-central-diabetes-insipidus-and-healthy-controls-100568096","NCT06676774","Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus and Healthy Controls","Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus (Arginine Vasopressin Deficiency) and Healthy Controls - the OxyMOTION-Study","OxyMOTION","Inclusion criteria healthy controls\n\n1. Adult healthy volunteers\n2. Matched for age, sex, BMI, and oestrogen replacement\u002Fmenopause\u002Fhormonal contraceptives to patients.\n3. No medication, except hormonal contraception\n\nInclusion criteria\n\n1. Adult patients with a confirmed diagnosis of AVP deficiency based on accepted criteria6\n2. Stable hormone replacement therapy for at least three months with desmopressin and, in case of additional anterior pituitary deficiencies, with the respective substitution therapies.\n\nExclusion criteria\n\n1. Participation in a trial with investigational drugs within 30 days\n2. Active substance use disorder within the last six months\n3. Consumption of alcoholic beverages \\>15 drinks\u002Fweek\n4. Current or previous psychotic disorder (e.g., schizophrenia spectrum disorder)\n5. Pregnancy and breastfeeding within the last eight weeks",{"count":84,"type":20},[86],"This study aims to investigate the potential beneficial effects of intranasal oxytocin compared to placebo on emotion recognition and acute psychosocial stress in patients with arginine vasopressin deficiency compared to matched healthy controls.",[26,113],"Diabetes Insipidus",[115],"intranasal oxytocin","2025-05-22",{"date":118,"type":37},"2025-05-23",{"date":120,"type":37},"2025-05-16",{"date":122,"type":20},"2027-02",{"name":43,"class":44}]